NCT03574844已完成不适用
Randomized, Double-blind, Placebo-controlled Clinical Study Evaluating the Effect of Oral Probiotic Yeast on the Composition of the Vaginal Microbiota in Healthy Women
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- S cerevisiae transfer from the gut to the vagina
研究概览
简要总结
This study is designed to evaluate the impact of oral consumption of the probiotic yeast CNCM I-3856 on healthy vaginal microbiota
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Caucasian or Asian women,
- •With regular menstrual cycles, assessed as 28 days ± 3 days,
- •With a normal vaginal flora : Nugent score ≤ 3,
- •With the same efficient contraception method since at least 3 months before the start of the study, and accepting to maintain this program over the study. Authorized contraception methods: hormonal contraception (pill, patch, implant and intrauterine device), tubal ligation, ESSURE system and copper intrauterine device (without hormone),
- •Agreeing to keep unchanged her intimate hygiene rules during the all duration of the study (same stable intimate hygiene habits since at least 3 months before the start of the study),
- •Good general and mental health compatible with the study participation and allowing to be followed in ambulatory way according to the investigator opinion: no clinically significant and relevant abnormalities of medical history or physical examination;
- •Having stable life habits since at least 3 months and accepting to maintain them stable during the study (dietary habits, tobacco and alcohol consumptions, physical activity and sexual activity),
- •Tobacco consumption ≤ 10 cigarettes per day,
- •Able and willing to participate to the study by complying with the protocol procedures (especially concerning study product consumption and biological samples collections), as evidenced by her dated and signed informed consent form,
- •Affiliated with a social security scheme,
- •Agreeing to be registered on the national file of volunteers participating in biomedical research.
排除标准
- •Having hypersensitivity history to one of the ingredients of the study products,
- •Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other uncontrolled metabolic disorder,
- •Suffering from a severe chronic disease (e.g. cancer, renal failure, hepatic or biliary disorders ongoing, chronic inflammatory digestive disease, arthritis, chronic respiratory trouble, chronic gastro-intestinal disorder, cardiac disease, immunodeficiency...) or diseases found to be inconsistent with the conduct of the study by the investigator (controlled arterial hypertension accepted),
- •Suffering from Sexually Transmitted Infection (STI) or Disease (STD) such as HIV (Human Immunodeficiency Virus), B and C hepatitis, HPV (Human PapillomaVirus), Chlamydia infection, syphilis, gonorrhea, genital herpes, etc,
- •Currently suffering or having suffer from bacterial, fungal, parasitic or viral infection of the uro-gynecological sphere (vaginitis, cystitis, cervix infection...), treated or not, in the 6 months previous to the study start,
- •Having medical history or current pathology which could affect the study results or expose the subject to an additional risk according to the investigator,
- •Currently pregnant, or lactating, intending to be pregnant within 2 months ahead or pregnancy and/or breastfeeding finished since less than 3 months,
- •Ongoing symptoms of vaginal and/or urinary infection (belong to symptoms questionnaire) at the moment of the V0 and V1 visits,
- •Recent history of radiotherapy (less than 6 months),
- •Menopausal or pre-menopausal,
- •With menstruation which usually lasts more than 7 days,
- •Under chronic treatment with corticosteroids and/or immune modulator (immunostimulant, immunosuppressant...) or last intake within 3 months before the start of the study,
- •Currently under medication or dietary supplement, oral or local, which could affect study parameters: antibiotic, antifungal, probiotic, prebiotic, symbiotic, phytoestrogens, etc, or stopped within a too short time window before study start (less than 4 weeks) ,
- •.- Having a lifestyle deemed incompatible with the study according to the investigator (specific diet (vegetarian, vegan, hypocolaric...), alcohol consumption > 2 glasses / day, physical activity > 10 hours / week...),
- •With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,
- •Planning to travel for a long time during the study duration or not able to be contacted for emergency reason during the study available,
- •Presenting a psychological or linguistic incapacity to understand and sign the informed consent,
- •Participating in another clinical trial or in exclusion period from a previous clinical trial,
- •Having received, during the last 12 months, countervailing indemnities for clinical trial higher or equal to 4500 Euros,
- •Under legal protection (guardianship, wardship) or deprived from her rights following judicial or administrative decision.
研究组 & 干预措施
Saccharomyces cerevisiae, dose 500
Experimental
Saccharomyces cerevisiae CNCM I-3856, 500 mg per day (2 capsules), for 4 weeks
干预措施: Saccharomyces cerevisiae, dose 500 (Dietary Supplement)
Saccharomyces cerevisiae, dose 1000
Experimental
Saccharomyces cerevisiae CNCM I-3856, 1 g per day (2 capsules), for 4 weeks
干预措施: Saccharomyces cerevisiae, dose 1000 (Dietary Supplement)
Placebo
Placebo Comparator
Maize starch and magnesium stearate, 1 g per day (2 capsules), for 4 weeks
干预措施: Placebo (Dietary Supplement)
结局指标
主要结局
S cerevisiae transfer from the gut to the vagina
时间窗: Day 28
Proportion of subjects presenting the yeast strain S cerevisiae CNCM I-3856 (presence) in their vaginal microbiota after a 4-week daily supplementation
次要结局
- Impact on 4 predominant Lactobacilli species(Day 7, Day 14, Day 21, Day 28, Day 42)
- Association between intestinal and vaginal microbiota for the presence of S cerevisiae CNCM I-3856(Day 7, Day 14, Day 21, Day 28, Day 42)
- Correlation between the quantity of S cerevisiae CNCM I-3856 (CFU/sample) in the intestinal microbiota and vaginal microbiota(Day 7, Day 14, Day 21, Day 28, Day 42)
- Presence of Candida albicans in the vaginal microbiota(Day 7, Day 14, Day 21, Day 28, Day 42)
- Evolution of the presence of Candida albicans in the vaginal microbiota(Day 7, Day 14, Day 21, Day 28, Day 42)
- S cerevisiae transfer from the gut to the vagina(Day 7, Day 14, Day 21, Day 42)
- Quantification of S cerevisiae in the vagina(Day 7, Day 14, Day 21, Day 28, Day 42)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the ElderlySARS CoV-2 InfectionElderlyNCT04756466Biosearch S.A.201
Unknown
1 期
Evaluation of the Safety and Effectiveness of a Probiotic Bacterium to Boost the Immune Response to Influenza VaccinesInfluenzaNCT00294788Probiomics Ltd300
已完成
不适用
A Study to Evaluate the Effect of Probiotic Supplement on Quality of LifeNon-cystic Fibrosis BronchiectasisChronic Obstructive Pulmonary DiseaseNCT05523180ResBiotic Nutrition, Inc.37
Unknown
不适用
A Study on Efficacy of Feeding N1115 Probiotic Supplement to Young ChildrenIntestinal Growth of Young ChildrenNCT03416595Junlebao Dairy Group Co., Ltd.60
已完成
不适用
Effect of Saccharomyces Cerevisiae on the Symptoms of Irritable Bowel SyndromeIrritable Bowel SyndromeNCT01613456Lesaffre International364